Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 May 15;9(5):e97325.
doi: 10.1371/journal.pone.0097325. eCollection 2014.

Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals

Affiliations
Observational Study

Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals

Dora E Corzo-Leon et al. PLoS One. .

Abstract

Introduction: Larger populations at risk, broader use of antibiotics and longer hospital stays have impacted on the incidence of Candida sp. bloodstream infections (CBSI).

Objective: To determine clinical and epidemiologic characteristics of patients with CBSI in two tertiary care reference medical institutions in Mexico City.

Design: Prospective and observational laboratory-based surveillance study conducted from 07/2008 to 06/2010.

Methods: All patients with CBSI were included. Identification and antifungal susceptibility were performed using CLSI M27-A3 standard procedures. Frequencies, Mann-Whitney U test or T test were used as needed. Risk factors were determined with multivariable analysis and binary logistic regression analysis.

Results: CBSI represented 3.8% of nosocomial bloodstream infections. Cumulative incidence was 2.8 per 1000 discharges (incidence rate: 0.38 per 1000 patient-days). C. albicans was the predominant species (46%), followed by C. tropicalis (26%). C. glabrata was isolated from patients with diabetes (50%), and elderly patients. Sixty-four patients (86%) received antifungals. Amphotericin-B deoxycholate (AmBD) was the most commonly used agent (66%). Overall mortality rate reached 46%, and risk factors for death were APACHE II score ≥ 16 (OR = 6.94, CI95% = 2.34-20.58, p<0.0001), and liver disease (OR = 186.11, CI95% = 7.61-4550.20, p = 0.001). Full susceptibility to fluconazole, AmBD and echinocandins among C. albicans, C. tropicalis, and C. parapsilosis was observed.

Conclusions: The cumulative incidence rate in these centers was higher than other reports from tertiary care hospitals from Latin America. Knowledge of local epidemiologic patterns permits the design of more specific strategies for prevention and preemptive therapy of CBSI.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have read the journal's policy and have the following conflicts: D. Corzo-Leon has no diclosures; A.L. Colombo has received research grants from Pfizer, MSD, United Medical and Luminex, medical education grants from Pfizer, MSD, United Medical and Astellas. He has also been a consultant for MSD, Pfizer, and Gilead; J.A. Cortes has received research grants and support to attend educational meetings from Pfizer and MSD; M. Nucci has received research grants from Pfizer and MSD and has acted as a consultant and speaker for Pfizer, MSD, Astellas and Gilead; P. Cornejo-Juarez has been a speaker for Merck, Stendhal and Astra Zeneca. She is in an advisory board in Astra-Zeneca and has received research grant from MSD; A Macias has no disclosures; F. de Queiroz-Telles has participated in Continuing education activities in laboratories for Astellas, MSD, Pfizer and United Medical, and in research activities in laboratories for Astellas, MSD and Pfizer; L. Ostrosky-Zeichner has received honoraria for speaking and consulting for Pfizer, Merck, Astellas. He has also recived research grants from Pfizer, Merck, and Astellas; I.N. Tiraboschi has been a speaker for Pfizer and Gilead; J. Zurita has been advisory board member and consultant for Pfizer and has received medical grants from Wyeth and MSD for participating in the SMART study; A. Ponce-de-Leon is speaker on behalf of MSD, Pfizer, Jannsen-Cilag, and Novartis, in addition, he received medical grants funded by MSD and Pfizer and has been an advisory board member for Pfizer, MSD and Jannsen-Cilag; J. Sifuentes-Osornio received grants from Astra-Zeneca, Senosian, Pfizer, MSD, and Sanofi-Pasteur, and is member of advisory board for Pfizer and MSD. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Similar articles

Cited by

References

    1. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133–163. - PMC - PubMed
    1. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, et al. (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37: 1612–1618. - PubMed
    1. Lipsett PA (2006) Surgical critical care: fungal infections in surgical patients. Crit Care Med 34(9 Suppl): S215–24. - PubMed
    1. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, et al. (2009) The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 16: 508–511. - PubMed
    1. Colombo AL, Nucci M, Park BJ, Nouer SA, Arthington-Skaggs B, et al. (2006) Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 44: 2816–2823. - PMC - PubMed

Publication types

MeSH terms